11 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Global Research in Paediatrics (GRiP)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2017,
Paediatric drugs (PD) lack appropriate testing. Most drugs have inadequate information about dosing regimen, dose adjustment and how to administer them. These are longstanding problems that unquestionably require concerted efforts at the international level. Both the US and the EU have introduced paediatric legislation that facilitates participation of children in research and pharmaceutical innov ...
Voir le projet
24
Participants partenaires
TERMINÉ
DEferiprone Evaluation in Paediatrics (DEEP)
Date du début: 1 janv. 2011, Date de fin: 31 août 2016,
"β-thalassaemia major is one of the most severe forms of chronic congenital anaemia. The recommended treatment consists in regular blood transfusions combined with chelating therapy to remove harmful iron accumulation in the body. The use of deferoxamine, the first chelating agent only available for subcutaneous administration is limited due to toxicity and the lack of compliance, despite its sat ...
Voir le projet
18
Participants partenaires
TERMINÉ
Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, affecting approximately 5% children in Europe. Methylphenidate (MPH) is the most-commonly prescribed medication for ADHD children; it is also increasingly used in ADHD adults. In 2007, the European Commission requested a referral to the Committee for Medicinal Products for Human Use ...
Voir le projet
17
Participants partenaires
TERMINÉ
Management of Resistance to Tyrosine Kinase Inhibitors with Advanced Nanosystems (NANORESISTANCE)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,
NANORESISTANCE introduces for the first time (i) receptor -independent targeting of Epidermal Growth Factor Receptor-kinase activity, (ii) nuclear delivery of anti-Epidermal Growth Factor Receptor therapy with novel grafting techniques and (iii) the deciphering of resistance and lack of responsiveness to anti-EGFR therapies in the preclinical setting with mathematical models of interstitial biodi ...
Voir le projet
7
Participants partenaires
TERMINÉ
Paediatric European Risperidone Studies (PERS)
Date du début: 1 mai 2010, Date de fin: 30 avr. 2015,
"Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in ado ...
Voir le projet
22
Participants partenaires
TERMINÉ
Suicidality: Treatment Occurring in Paediatrics (STOP)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,
The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Rela ...
Voir le projet
19
Participants partenaires
TERMINÉ
Embryonic Stem cell-based Novel Alternative Testing Strategies (ESNATS)
Date du début: 1 avr. 2008, Date de fin: 30 sept. 2013,
"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to ...
Voir le projet
34
Participants partenaires
TERMINÉ
Assessment of the hazard and opportunities of using carbon nanotubes as a new nanocarrier for drug delivery in neural tissue (NANONEUROHOP)
Date du début: 1 juil. 2011, Date de fin: 30 juin 2013,
"While neurodegenerative disorders and brain cancers increase in the population, current therapies have shown their limits. But thanks to recent advancements in nanosciences and nanotechnologies, new therapeutic opportunities are offered based on the development of nanoscale drug delivery systems. Among those, carbon nanotubes (CNT) have shown promising applications for therapy of a broad range of ...
Voir le projet
2
Participants partenaires
TERMINÉ
Contaminant mixtures and human reproductive health - novel strategies for health impact and risk assessment of endocrine disrupters (CONTAMED)
Date du début: 1 mai 2008, Date de fin: 31 oct. 2012,
"Disruption of hormonal signalling in fetal life can irreversibly affect human development and reproductive health at a later age. Of considerable concern in Europe is a decline in male semen quality and a high prevalence of congenital malformations and hormone-dependent cancers. Although it appears plausible that environmental chemicals with endocrine activity may be involved in the causation of ...
Voir le projet
9
Participants partenaires
TERMINÉ
Image-controlled Ultrasound-induced Drug Delivery (SonoDrugs)
Date du début: 1 nov. 2008, Date de fin: 31 oct. 2012,
The demographic changes in Europe towards an aging society will coincide with increasing morbidity of the population. European citizens need improved access to state-of-the-art medical care especially in oncology and cardiology, while keeping expenditures on healthcare affordable. New therapeutic options such as externally triggered local drug release at the diseased area hold promise to solve urg ...
Voir le projet
18
Participants partenaires
TERMINÉ
In the XXI century EU pharmacists will play an increasingly important role as partners in the efficient use of the health care resources of the EU (community and hospital pharmacists). They will also be major players in the development of the EU pharmaceutical industry (industrial pharmacists). Whilst abiding by the recommendations for the duration and course content for EU pharmacy education and ...
Voir le projet